MARKET

NVAX

NVAX

Novavax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

179.33
-4.67
-2.54%
After Hours: 181.00 +1.67 +0.93% 19:59 07/30 EDT
OPEN
183.12
PREV CLOSE
184.00
HIGH
186.34
LOW
178.10
VOLUME
2.20M
TURNOVER
--
52 WEEK HIGH
331.68
52 WEEK LOW
76.59
MARKET CAP
13.29B
P/E (TTM)
-19.3807
1D
5D
1M
3M
1Y
5Y
Vaccine Mandates Could Be Good News for Vaccine Makers
marketwatch.com · 8h ago
Novavax Inc. stock falls Friday, underperforms market
marketwatch.com · 1d ago
Fully vaccinated people made up 74% of cases in a COVID-19 outbreak in Massachusetts - CDC
On Friday, the Centers for Disease Control and Prevention (CDC) released data supporting the view that the COVID-19 Delta variant can cause infections even among fully vaccinated people. The CDC
Seekingalpha · 1d ago
COVID-19 Delta variant is as contagious as chickenpox, CDC report says - NYT
COVID-19 Delta variant is as contagious as chickenpox and more transmissible than other viral infections such as MERS, SARS, Ebola, the common cold, the seasonal flu, and smallpox, according to
Seekingalpha · 1d ago
Novavax Inc. stock underperforms Thursday when compared to competitors
marketwatch.com · 2d ago
Latest Covid Spike Means You May Want a Booster Shot
marketwatch.com · 2d ago
Analysts Estimate Novavax (NVAX) to Report a Decline in Earnings: What to Look Out for
Zacks.com · 2d ago
Novavax Inc. stock outperforms market on strong trading day
marketwatch.com · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVAX. Analyze the recent business situations of Novavax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVAX stock price target is 262.00 with a high estimate of 294.00 and a low estimate of 223.00.
EPS
Institutional Holdings
Institutions: 436
Institutional Holdings: 46.33M
% Owned: 62.53%
Shares Outstanding: 74.09M
TypeInstitutionsShares
Increased
98
7.19M
New
100
2.98M
Decreased
137
4.48M
Sold Out
58
1.92M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman/Independent Director
James Young
President/Chief Executive Officer/Director
Stanley Erck
Chief Financial Officer/Executive Vice President
John Trizzino
Corporate Executive
Gregory Glenn
Chief Operating Officer/Executive Vice President
Rick Crowley
Chief Human Resource Officer/Executive Vice President
Jill Hoyt
Executive Vice President/Chief Compliance Officer
Troy Morgan
Executive Vice President/Secretary
John Herrmann
Executive Vice President
Filip Dubovsky
Senior Vice President/Director of Sales
Frank Czworka
Senior Vice President/Director of Investor Relations
Silvia Taylor
Senior Vice President
Madelyn Caltabiano
Senior Vice President
Brian Rosen
Senior Vice President
Gale Smith
Senior Vice President
Henrietta Ukwu
Senior Vice President
Brian Webb
Director
Rajiv Modi
Independent Director
Gregg Alton
Independent Director
Richard Douglas
Independent Director
Gary Evans
Independent Director
Rachel King
Independent Director
Margaret Mcglynn
Independent Director
Michael Mcmanus
Independent Director
David Mott
No Data
  • All
  • Financials
  • Insiders
More
About NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Webull offers kinds of Novavax, Inc. stock information, including NASDAQ:NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVAX stock methods without spending real money on the virtual paper trading platform.